Atrion (NASDAQ:ATRI) was downgraded by equities research analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Monday.
Atrion (NASDAQ:ATRI) opened at $641.40 on Monday. The firm has a market cap of $1,190.00, a PE ratio of 37.43 and a beta of 0.85. Atrion has a 12-month low of $454.10 and a 12-month high of $694.00.
Atrion (NASDAQ:ATRI) last posted its quarterly earnings data on Wednesday, November 8th. The medical instruments supplier reported $4.29 earnings per share for the quarter. The company had revenue of $37.90 million during the quarter. Atrion had a net margin of 22.98% and a return on equity of 18.34%.
A number of large investors have recently bought and sold shares of ATRI. BNP Paribas Arbitrage SA boosted its position in Atrion by 4,800.0% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 196 shares of the medical instruments supplier’s stock valued at $126,000 after buying an additional 192 shares during the last quarter. Legal & General Group Plc boosted its position in Atrion by 4.3% in the 2nd quarter. Legal & General Group Plc now owns 336 shares of the medical instruments supplier’s stock valued at $216,000 after buying an additional 14 shares during the last quarter. Victory Capital Management Inc. lifted its position in shares of Atrion by 17.7% during the second quarter. Victory Capital Management Inc. now owns 438 shares of the medical instruments supplier’s stock worth $282,000 after purchasing an additional 66 shares during the last quarter. Capital Analysts LLC bought a new position in shares of Atrion during the second quarter worth about $434,000. Finally, Voya Investment Management LLC lifted its position in shares of Atrion by 10.2% during the second quarter. Voya Investment Management LLC now owns 755 shares of the medical instruments supplier’s stock worth $486,000 after purchasing an additional 70 shares during the last quarter. 59.01% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: This report was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and international copyright laws. The original version of this report can be read at https://sportsperspectives.com/2017/12/20/atrion-atri-rating-lowered-to-strong-sell-at-bidaskclub.html.
Atrion Company Profile
Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety.
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.